TY - JOUR T1 - Novel Delivery Systems for Improving the Clinical Use of Peptides JF - Pharmacological Reviews JO - Pharmacol Rev SP - 541 LP - 561 DO - 10.1124/pr.113.008367 VL - 67 IS - 3 AU - Miia Kovalainen AU - Juha Mönkäre AU - Joakim Riikonen AU - Ullamari Pesonen AU - Maria Vlasova AU - Jarno Salonen AU - Vesa-Pekka Lehto AU - Kristiina Järvinen AU - Karl-Heinz Herzig A2 - Koulu, Markku Y1 - 2015/07/01 UR - http://pharmrev.aspetjournals.org/content/67/3/541.abstract N2 - Peptides have long been recognized as a promising group of therapeutic substances to treat various diseases. Delivery systems for peptides have been under development since the discovery of insulin for the treatment of diabetes. The challenge of using peptides as drugs arises from their poor bioavailability resulting from the low permeability of biological membranes and their instability. Currently, subcutaneous injection is clinically the most common administration route for peptides. This route is cost-effective and suitable for self-administration, and the development of appropriate dosing equipment has made performing the repeated injections relatively easy; however, only few clinical subcutaneous peptide delivery systems provide sustained peptide release. As a result, frequent injections are needed, which may cause discomfort and additional risks resulting from a poor administration technique. Controlled peptide delivery systems, able to provide required therapeutic plasma concentrations over an extended period, are needed to increase peptide safety and patient compliancy. In this review, we summarize the current peptidergic drugs, future developments, and parenteral peptide delivery systems. Special emphasis is given to porous silicon, a novel material in peptide delivery. Biodegradable and biocompatible porous silicon possesses some unique properties, such as the ability to carry exceptional high peptide payloads and to modify peptide release extensively. We have successfully developed porous silicon as a carrier material for improved parenteral peptide delivery. Nanotechnology, with its different delivery systems, will enable better use of peptides in several therapeutic applications in the near future. ER -